Skip to main content

Table 2 Main original results of each study

From: The effect of animal-assisted interventions on the course of neurological diseases: a systematic review

Study

Duration (week)

Occasion/week

Lenght (minutes)

N_AAI

N_OAT

N_PC

Outcome

Mean (± SD)_AAI_baseline

Mean (± SD)_OAT_baseline

Mean (± SD)_PC_baseline

Mean (± SD)_AAI_follow up

Mean (± SD)_OAT_follow up

Mean (± SD)_PC_follow up

Beinotti et al. 2010 [12]

16

1

no data

10

-

10

Fugl-Meyer balancea

14,7 (3,8)

-

13,1 (6,2)

18,5 (3,6)

-

13,1 (7,3)

Fugl-Meyer lower limbs

11,4 (1,6)

11,1 (0,9)

11,6 (1,3)

11,2 (1,8)

BBSa

46,1 (12,9)

44,3 (12,3)

49 (13)

45,1 (14,2)

FAC'

3,06 (0,8)

3,2 (1,0)

3,8 (0,9)

3,4 (1)

gait cadence

96,1 (24,7)

96,5 (25,8)

92,5 (21)

100,9 (17,9)

gait speed

0,7 (0,2)

0,8 (0,4)

0,8 (0,2)

0,8 (0,3)

Beinotti et al. 2013 [13]

16

1

30

12

-

12

MOSF36 SF-functional capacitya

40,5 (15,7)

-

50 (19,7)

51,5 (14,3)

-

40 (26)

MOSF36 SF-physical aspectsa

57,5 (35,5)

70 (28,4)

100 (0)

75 (35,4)

MOSF36 SF-pain

97,5 (7,9)

63,9 (30,8)

91,9 (18,5)

70,6 (27,3)

MOSF36 SF-general health state

75,3 (17,8)

75 (24,4)

85,9 (15,5)

77,7 (20,9)

MOSF36 SF-vitality

63 (10,1)

57,5 (24)

77,5 (18,1)

61 (22,7)

MOSF36 SF-social aspects

81,3 (19,3)

48,8 (28,5)

90 (12,9)

58,8 (36,8)

MOSF36 SF-emotional aspects

83,3 (32,4)

50 (36)

96,7 (10,5)

70 (39,9)

MOSF36 SF-mental healtha

73,2 (22,5)

72,4 (13,7)

83,2 (16,9)

68,8 (18,5)

Berardi et al. 2022 [14]

5

2

45

17

-

-

SDS'

42 (7,45)

-

-

34 (6,84)

-

-

UPDRS'

16 (8,45)

11 (7,43)

RAS'

30 (6,12)

38 (4,05)

Tinetti (total)'

16 (4,70)

20 (4,82)

PDQ 39 (total)'

70 (29,09)

52 (19,77)

Bunketorp-Kall et al. 2020 [15]

12

2

no data

43

-

-

M-MAS UAS

50,33 (6,1)

-

-

no data

-

-

BBS

50,4 (5,7)

TUG

14,3 (8)

Timed 10 m-WT-self selected'

12,7 (6,1)

Timed 10 m-WT-fast'

9,2 (4,8)

Bunketorp-Kall et al. 2019 [16]

12

2

no data

41

41

41

10 m-WT Time: self selecteda

15,05

10,03

13,37

12,83

9,49

13,74

10 m-WT Time: fasta

9,71

7,26

9,84

8,52

7,12

10,72

6MWT

361,29

437,69

374,89

388,35

453,38

383,49

M-MAS UAS

49,63

51,39

50,8

50,76

52,01

50,98

Bunketorp-Kall et al. 2017 [17]

12

2

no data

41

41

41

SISa

exact baseline data are not available

exact follow up data are not available, within group changes from baseline to follow up are publicated

TUGa'

BBSa'

BDL-BS

Grip strength (mean, L)

Grip strength (mean, R)

BNIS

LNS

Lee et al., 2014 [18]

8

3

30

15

15

-

BBS'

40,4 (1,5)

40,5 (1,5)

-

42,7 (3,2)

41,7 (5,1)

-

gait velocity'

38,3 (0,4)

38,4 (0,4)

39,6 (0,8)

38,8 (0,8)

step length asymmetry ratio'

0,32 (0,05)

0,32 (0,04)

0,19 (0,05)

0,29 (0,06)

Macauley, 2006 [19]

12

1

30

3

3

-

WAB

74,37

74,37

-

75,4

73,6

-

CSQ

-

-

-

8,8

7,5

-

Machová et al. 2019 [20]

6

2

20

6

-

9

Likert scale for mood

1

exact baseline data are not available

1

3,5

exact follow up data are not available

1

diastolic blood pressure

72,5

exact baseline data are not available

77

75

exact follow up data are not available

72

systolic blood pressure

exact baseline data are not available

exact follow up data are not available

heart rate

83

exact baseline data are not available

71

76

exact follow up data are not available

68

Barthel indexa

27

exact baseline data are not available

45

45

exact follow up data are not available

41

Peppe et al. 2017 [21]

5

1

60

3

-

-

GA Gait Velocity (m/s)

0,83

-

-

0,81

-

-

GA Stride Length (m)

0,95

-

-

1,59

-

-

GA Stance %

70,2

-

-

65,1

-

-

GA Double Stance %

19,7

-

-

13,8

-

-

UPDRS part III

19,6

-

-

13

-

-

Attention and Executive functioning:Stroop Test Resistance to interference-Accuracy

19,5

-

-

26,5

-

-

Attention and Executive functioning: Stroop Test Resistance to interference-Response Time

151,5

-

-

139,5

-

-

Attention and Executive functioning: Trail Making Test-Subtest A

57,3

-

-

57,6

-

-

Attention and Executive functioning:Trail Making Test-Subtest B

161

-

-

150,6

-

-

STAI-Y1

30,3

-

-

30,3

-

-

STAI-Y2

49,6

-

-

38,6

-

-

GDS

9,3

-

-

5

-

-

AES

32,6

-

-

29

-

-

Rondeau et al. 2010 [22]

3

4

60

4

4

-

10 m-WSa

28,75

-

-

15,37

-

-

GA minor deviation

17,5

-

-

6,25

-

-

GA major deviation

15,87

-

-

6,5

-

-

Sunwoo et al. 2012 [23]

8

2

30

8

8

-

K-BBS'

38,9 (11,9)

38,9 (13,1)

-

42,0 (12,0)

38,9 (11,9)

-

POMA'

20,1 (5,3)

19,8 (5,7)

22,4 (5,5)

20,1 (5,3)

10 m-WT'

61,1 (56,0)

56,9 (50,1)

47,8 (44,0)

61,1 (56,0)

FAC

4,3 (0,7)

4,3 (0,7)

4,3 (0,7)

4,3 (0,7)

K-BDI

7,8 (8,1)

9,5 (9,8)

7,0 (8,9)

7,8 (8,1)

Ham-D

3,9 (3,6)

4,4 (4,1)

3,1 (3,9)

3,9 (3,6)

K-MBI

83,1 (8,1)

83,1 (7,6)

84,1 (8,5)

83,1 (8,1)

Pálsdóttir et al. 2020 [24]

52

1

90

14

98

29

OVal-pd concretea

2,5

-

2,6

2,8

-

2,6

OVal-pd symbolic

2,3

-

2,4

2,6

-

2,4

OVal-pd self rewarding

2,3

-

2,4

2,7

-

2,4

SMBQ listlessness

5

-

4,5

4,7

-

4,5

SMBQ tension

4,4

-

3,2

4

-

3,1

SMBQ emotional and physical exhaustion

4,5

-

3,8

4,2

-

3,9

SMBQ cognitive weariness

3,7

-

3,7

4,1

-

3,5

EQ-VASa

55

-

62

65

-

62

  1. aSignificant difference between intervention and control group, 'Significant difference within the intervention group, p < 0.05; OAT other additional therapy, PC Passive control